Creative Bioarray announced the release of its cutting-edge solutions powered by patient-derived organoid technology
NEW YORK, NY, April 16, 2026 /24-7PressRelease/ — Creative Bioarray is a company providing specialized technology, products, materials, and services for biopharmaceutical and life science researchers in order to advance oncology and immuno-oncology. Recently, Creative Bioarray announced the release of its cutting-edge solutions powered by patient-derived organoid technology, including predictive insights into patient responses, enabling researchers to develop targeted therapies and improve drug development efficiency.
As inter-patient heterogeneity continues to be one of the major challenges in oncology drug development and clinical translation, the need for reliable and representative preclinical models has become increasingly urgent. 2D cancer cell lines and animal models can not accurately mimic the complexity of human tumors, resulting in a high rate of clinical failure for novel therapeutics. In contrast, Creative Bioarray’s PDO-based drug screening platform bridges the gap between 2d cell lines and in vivo models, offering a more predictive tool for evaluating drug efficacy, resistance mechanisms, and personalized treatment strategies.
“Our PDO-based drug screening technology marks a significant breakthrough in cancer research capabilities,” stated Hannah Cole, a spokesperson for Creative Bioarray. “By utilizing organoids derived from patient tissues, researchers can now bridge the gap between laboratory research and clinical practice, thereby ensuring that their findings are more predictive and better applicable to real-world clinical settings.”
Creative Bioarray offers extensive tumor coverage, supporting the construction of PDO models and drug screening across more than 20 types of solid tumors—including colorectal, pancreatic, breast, lung, and gastric cancers. This comprehensive model library provides a robust foundation for in-depth research into various malignancies, thereby significantly enhancing the potential for discovering effective therapeutic solutions.
Furthermore, Creative Bioarray is specifically designed to support hypothesis-driven research and large-scale screening projects; it employs automated workflows and is compatible with various microplate formats (including 96-well, 384-well, and 1536-well plates). This high degree of adaptability enables rapid compound screening, thereby significantly accelerating the drug discovery and development process.
Creative Bioarray supports the screening of diverse compound libraries—encompassing FDA-approved drugs, natural products, and client-provided compounds—enabling researchers to explore a wide spectrum of therapeutic strategies, ranging from drug repurposing to the development of combination therapy regimens.
More importantly, Creative Bioarray offers a diverse range of screening strategies, including single-agent sensitivity testing, assessment of drug combinations, and various large-scale, high-throughput assays. This versatility facilitates an in-depth analysis of tumor response mechanisms to treatment, patterns of drug resistance, and synergistic interactions between drugs.
Future Applications and Impacts
Amidst the ongoing advancements in the field of personalized medicine, Creative Bioarray’s PDO (Patient-Derived Organoid)-based drug screening services introduce a transformative new paradigm to cancer therapeutics research. The future prospects for these applications are poised to extend beyond the realm of oncology, expanding into other therapeutic areas—including infectious diseases and chronic conditions. Creative Bioarray remains steadfast in its commitment to providing the scientific community with world-class services, thereby tangibly enhancing both the quality and clinical relevance of drug discovery and development efforts.
About Creative Bioarray
Creative Bioarray is a leading provider of biological research services and solutions. We specialize in high-quality cell culture models, innovative drug testing, and cutting-edge research tools, empowering scientists to accelerate their discoveries in life sciences. Leverage our state-of-the-art technology to develop new models that meet your specific needs.
—
For the original version of this press release, please visit 24-7PressRelease.com here
